Ignite Creation Date:
2024-05-06 @ 7:27 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06017245
Status:
COMPLETED
Last Update Posted:
2024-01-17
First Post:
2023-08-24
Brief Title:
The Bone-Myoregulation Reflex and Development of Sarcopenia in Osteoporosis
Sponsor:
Istanbul Physical Medicine Rehabilitation Training and Research Hospital
Organization:
Istanbul Physical Medicine Rehabilitation Training and Research Hospital
Study Overview
Official Title:
Could the Bone-Myoregulation Reflex Explain the Development of Sarcopenia in Postmenopausal and Senile Osteoporosis
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Bone and skeletal muscle are in a single unit that interacts with each other structurally and functionally The aim of this study is to determine the contribution of bone myoregulation reflex as a neuronal crosstalk mechanism on the development of sarcopenia in postmenopausal and senile osteoporosis
Detailed Description:
Bone and skeletal muscle are in a single unit that interacts with each other structurally and functionally While myokines synthesized and released in skeletal muscle modulate the bone formation and destruction process osteokines synthesized and released by bone cells have positive or negative effects on muscle 456789 In addition to humoral crosstalk mechanisms between muscle and bone there is also a neuronal crosstalk mechanism defined as bone myoregulation reflex The aim of this study is to determine the contribution of bone myoregulation reflex as a neuronal crosstalk mechanism on the development of sarcopenia in postmenopausal and senile osteoporosis 1011121314 Osteoporotic cases would be determined by standard DXA measurements
The vibration will be applied with the PowerPlate Pro5 whole-body vibration London UK device The vibration amplitude will be 2 mm The vibration frequency will be 30 33 and 36 Hz Each vibration frequency will be applied for 45 seconds A 5-second rest period will be applied between vibrations of 45 seconds
Surface EMG recordings will be taken from the right soleus muscle using the bipolar technique A pair of self-adhesive AgAgCl Redline electrodes will be adhered to the skin according to the SENIAM protocol2 Recordings will be taken in the 1-500 Hz frequency band Surface electromyography EMG recordings will be taken with a PowerLab ADInstruments Oxford UK data recorder with a sample rate of 20 KHz EMG recordings will be analyzed offline with LabChart7 Pro version 738 ADInstruments Oxford UK The acceleration measurement data will be recorded with the PowerLab ADInstrument London data acquisition simultaneously with the EMG recording Acceleration recording will be made with a sample rate of 20 KHz
The vibration will be applied with the PowerPlate Pro5 whole-body vibration London UK device The vibration amplitude will be 2 mm The vibration frequency will be 30 33 and 36 Hz Each vibration frequency will be applied for 45 seconds A 5-second rest period will be applied between vibrations of 45 seconds
Surface EMG recordings will be taken from the right soleus muscle using the bipolar technique A pair of self-adhesive AgAgCl Redline electrodes will be adhered to the skin according to the SENIAM protocol2 Recordings will be taken in the 1-500 Hz frequency band Surface electromyography EMG recordings will be taken with a PowerLab ADInstruments Oxford UK data recorder with a sample rate of 20 KHz EMG recordings will be analyzed offline with LabChart7 Pro version 738 ADInstruments Oxford UK The acceleration measurement data will be recorded with the PowerLab ADInstrument London data acquisition simultaneously with the EMG recording Acceleration recording will be made with a sample rate of 20 KHz
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None